Neuroimaging in neurodegenerative dementias

Seminars in Neurology

Volumn 32, Issue 4, 2012, Pages 347-360

  McGinnis, Scottm ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

18F fluorodeoxyglucose positron emission tomography (FDG PET); Alzheimer's disease; amyloid positron emission tomography; dementia; dementia with Lewy bodies; diffusion tensor imaging (DTI); dopamine transporter (DAT) imaging; frontotemporal dementia; functional connectivity magnetic resonance imaging (fcMRI); functional magnetic resonance imaging (fMRI); magnetic resonance imaging (MRI); neurodegeneration; neuroimaging

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; ARTICLE; BOLD SIGNAL; BRAIN CORTEX ATROPHY; BRAIN REGION; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; FRONTAL CORTEX; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HETEROZYGOTE; HUMAN; MIDDLE TEMPORAL GYRUS; NEUROIMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SEMANTIC DEMENTIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DEMENTIA; HUMANS; NEURODEGENERATIVE DISEASES; NEUROIMAGING;

EID: 84872933404     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1331808     Document Type: Article

References (165)

1. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC American Psychiatric Association: 1987
2. Pievani M., de Haan W., Wu T., Seeley W. W., Frisoni G. B. Functional network disruption in the degenerative dementias. Lancet Neurol: 2011; 10 9 829 843
3. Fox M. D., Raichle M. E. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci: 2007; 8 9 700 711 (Pubitemid 47283145)
4. Smith S. M., Fox P. T., Miller K. L., et al. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci U S A: 2009; 106 31 13040 13045
5. Buckner R. L., Snyder A. Z., Shannon B. J., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci: 2005; 25 34 7709 7717 (Pubitemid 41208641)
6. Seeley W. W., Crawford R. K., Zhou J., Miller B. L., Greicius M. D. Neurodegenerative diseases target large-scale human brain networks. Neuron: 2009; 62 1 42 52
7. Raj A., Kuceyeski A., Weiner M. A network diffusion model of disease progression in dementia. Neuron: 2012; 73 6 1204 1215
8. Warren J. D., Rohrer J. D., Hardy J. Disintegrating brain networks: from syndromes to molecular nexopathies. Neuron: 2012; 73 6 1060 1062
9. Zhou J., Gennatas E. D., Kramer J. H., Miller B. L., Seeley W. W. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron: 2012; 73 6 1216 1227
10. Petersen R. C. Clinical practice. Mild cognitive impairment. N Engl J Med: 2011; 364 23 2227 2234
11. Morris J. C. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord: 2005; 19 3 163 165 (Pubitemid 41545853)
12. Sperling R. A., Jack C. R. Jr, Aisen P. S. Testing the right target and right drug at the right stage. Sci Transl Med: 2011; 3 111 111cm133
13. Jack C. R. Jr, Knopman D. S., Jagust W. J., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol: 2010; 9 1 119 128
14. Sperling R. A., Aisen P. S., Beckett L. A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement: 2011; 7 3 280 292
15. Garre-Olmo J., Genís Batlle D., del Mar Fernández M., et al. Registry of Dementia of Girona Study Group (ReDeGi Study Group) Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology: 2010; 75 14 1249 1255
16. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol: 2011; 7 3 137 152
17. Hyman B. T., Phelps C. H., Beach T. G., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement: 2012; 8 1 1 13
18. Goldman J. S., Hahn S. E., Catania J. W., et al. American College of Medical Genetics and the National Society of Genetic Counselors Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med: 2011; 13 6 597 605
19. Bird T. D. Genetic aspects of Alzheimer disease. Genet Med: 2008; 10 4 231 239 (Pubitemid 351544124)
20. Balasa M., Gelpi E., Antonell A., et al. Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology: 2011; 76 20 1720 1725
21. Koedam E. L., Lauffer V., van der Vlies A. E., van der Flier W. M., Scheltens P., Pijnenburg Y. A. Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis: 2010; 19 4 1401 1408
22. Murray M. E., Graff-Radford N. R., Ross O. A., Petersen R. C., Duara R., Dickson D. W. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol: 2011; 10 9 785 796
23. Jack C. R. Jr. Alliance for aging research AD biomarkers work group: structural MRI. Neurobiol Aging: 2011; 32 01 S48 S57
24. Dubois B., Feldman H. H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol: 2007; 6 8 734 746 (Pubitemid 47058377)
25. Scheltens P., Leys D., Barkhof F., et al. Atrophy of medial temporal lobes on MRI in "probableo" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry: 1992; 55 10 967 972
26. Albert M. S., DeKosky S. T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement: 2011; 7 3 270 279
27. McKhann G. M., Knopman D. S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement: 2011; 7 3 263 269
28. Fischl B., van der Kouwe A., Destrieux C., et al. Automatically parcellating the human cerebral cortex. Cereb Cortex: 2004; 14 1 11 22 (Pubitemid 38018050)
29. Fox N. C., Freeborough P. A., Rossor M. N. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet: 1996; 348 9020 94 97 (Pubitemid 26234357)
30. Freeborough P. A., Fox N. C. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging: 1997; 16 5 623 629 (Pubitemid 127767641)
31. Davatzikos C., Xu F., An Y., Fan Y., Resnick S. M. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain: 2009; 132 Pt 8 2026 2035
32. Klöppel S., Stonnington C. M., Chu C., et al. Automatic classification of MR scans in Alzheimer's disease. Brain: 2008; 131 Pt 3 681 689 (Pubitemid 351294712)
33. Casanova R., Whitlow C. T., Wagner B., et al. High dimensional classification of structural MRI Alzheimer's disease data based on large scale regularization. Front Neuroinform: 2011; 5 22
34. Vemuri P., Gunter J. L., Senjem M. L., et al. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage: 2008; 39 3 1186 1197
35. Apostolova L. G., Dutton R. A., Dinov I. D., et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol: 2006; 63 5 693 699
36. Jack C. R. Jr, Petersen R. C., Xu Y. C., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology: 1999; 52 7 1397 1403 (Pubitemid 29190530)
37. Morra J. H., Tu Z., Apostolova L. G., et al. Alzheimer's Disease Neuroimaging Initiative Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage: 2009; 45 1, Suppl S3 S15
38. Apostolova L. G., Mosconi L., Thompson P. M., et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging: 2010; 31 7 1077 1088
39. Thompson P. M., Apostolova L. G. Computational anatomical methods as applied to ageing and dementia. Br J Radiol: 2007; 80 Spec No 2 S78 S91 (Pubitemid 351799334)
40. Ashburner J., Friston K. J. Voxel-based morphometry-the methods. Neuroimage: 2000; 11 6 Pt 1 805 821
41. Karas G. B., Scheltens P., Rombouts S. A., et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage: 2004; 23 2 708 716 (Pubitemid 39370621)
42. Whitwell J. L., Shiung M. M., Przybelski S. A., et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology: 2008; 70 7 512 520 (Pubitemid 351653375)
43. Chételat G., Landeau B., Eustache F., et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage: 2005; 27 4 934 946 (Pubitemid 41317262)
44. Fischl B., Dale A. M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A: 2000; 97 20 11050 11055
45. Rosas H. D., Liu A. K., Hersch S., et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology: 2002; 58 5 695 701 (Pubitemid 34211546)
46. Apostolova L. G., Steiner C. A., Akopyan G. G., et al. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol: 2007; 64 10 1489 1495 (Pubitemid 47572672)
47. Dickerson B. C., Bakkour A., Salat D. H., et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex: 2009; 19 3 497 510
48. Lerch J. P., Pruessner J. C., Zijdenbos A., Hampel H., Teipel S. J., Evans A. C. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex: 2005; 15 7 995 1001 (Pubitemid 40848068)
49. Bakkour A., Morris J. C., Dickerson B. C. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology: 2009; 72 12 1048 1055
50. Dickerson B. C., Stoub T. R., Shah R. C., et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology: 2011; 76 16 1395 1402
51. Jack C. R. Jr, Dickson D. W., Parisi J. E., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology: 2002; 58 5 750 757 (Pubitemid 34211554)
52. Whitwell J. L., Josephs K. A., Murray M. E., et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology: 2008; 71 10 743 749
53. Vemuri P., Whitwell J. L., Kantarci K., et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage: 2008; 42 2 559 567
54. Silverman D. H. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med: 2004; 45 4 594 607 (Pubitemid 47618590)
55. Matsuda H. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med: 2007; 48 8 1289 1300 (Pubitemid 47242794)
56. Jagust W., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology: 2007; 69 9 871 877 (Pubitemid 47329586)
57. Silverman D. H., Small G. W., Chang C. Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA: 2001; 286 17 2120 2127 (Pubitemid 34041597)
58. Reiman E. M. Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging: 2011; 32 01 S44 S47
59. Ikonomovic M. D., Klunk W. E., Abrahamson E. E., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain: 2008; 131 Pt 6 1630 1645 (Pubitemid 351806448)
60. Mirra S. S., Heyman A., McKeel D., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology: 1991; 41 4 479 486
61. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging: 1997; 18 4, Suppl S1 S2
62. Klunk W. E. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging: 2011; 32 01 S20 S36
63. Clark C. M., Schneider J. A., Bedell B. J., et al. AV45-A07 Study Group Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA: 2011; 305 3 275 283
64. Yang L., Rieves D., Ganley C. Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med: 2012; 367 10 885 887
65. Bateman R. J., Xiong C., Benzinger T. L., et al. Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med: 2012; 367 9 795 804
66. Schwindt G. C., Black S. E. Functional imaging studies of episodic memory in Alzheimer's disease: a quantitative meta-analysis. Neuroimage: 2009; 45 1 181 190
67. Sperling R. A., Dickerson B. C., Pihlajamaki M., et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med: 2010; 12 1 27 43
68. Sperling R. Potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol Aging: 2011; 32 01 S37 S43
69. Van Dijk K. R., Sperling R. A. Defaulting on the default network: increased risk for dementia. Neurology: 2011; 76 6 498 500
70. Greicius M. D., Srivastava G., Reiss A. L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A: 2004; 101 13 4637 4642 (Pubitemid 38437463)
71. Rombouts S. A., Damoiseaux J. S., Goekoop R., et al. Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp: 2009; 30 1 256 266
72. Petrella J. R., Sheldon F. C., Prince S. E., Calhoun V. D., Doraiswamy P. M. Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology: 2011; 76 6 511 517
73. Damoiseaux J. S. Resting-state fMRI as a biomarker for Alzheimer's disease? Alzheimers Res Ther: 2012; 4 2 8
74. Tang-Wai D. F., Graff-Radford N. R., Boeve B. F., et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology: 2004; 63 7 1168 1174 (Pubitemid 39350012)
75. Crutch S. J., Lehmann M., Schott J. M., Rabinovici G. D., Rossor M. N., Fox N. C. Posterior cortical atrophy. Lancet Neurol: 2012; 11 2 170 178
76. Lehmann M., Crutch S. J., Ridgway G. R., et al. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. Neurobiol Aging: 2011; 32 8 1466 1476
77. Gorno-Tempini M. L., Dronkers N. F., Rankin K. P., et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol: 2004; 55 3 335 346 (Pubitemid 38269585)
78. Gorno-Tempini M. L., Hillis A. E., Weintraub S., et al. Classification of primary progressive aphasia and its variants. Neurology: 2011; 76 11 1006 1014
79. Johnson J. K., Head E., Kim R., Starr A., Cotman C. W. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol: 1999; 56 10 1233 1239 (Pubitemid 29473215)
80. Whitwell J. L., Jack C. R. Jr, Przybelski S. A., et al. Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol Aging: 2011; 32 9 1531 1541
81. Warren J. D., Fletcher P. D., Golden H. L. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol: 2012; 8 8 451 464
82. Migliaccio R., Agosta F., Rascovsky K., et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology: 2009; 73 19 1571 1578
83. Vemuri P., Simon G., Kantarci K., et al. Antemortem differential diagnosis of dementia pathology using structural MRI: differential-STAND. Neuroimage: 2011; 55 2 522 531
84. Rabinovici G. D., Furst A. J., Alkalay A., et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain: 2010; 133 Pt 2 512 528
85. Rosenbloom M. H., Alkalay A., Agarwal N., et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology: 2011; 76 21 1789 1796
86. McKeith I., Mintzer J., Aarsland D., et al. International Psychogeriatric Association Expert Meeting on DLB Dementia with Lewy bodies. Lancet Neurol: 2004; 3 1 19 28 (Pubitemid 38018924)
87. McKeith I. G., Dickson D. W., Lowe J., et al. Consortium on DLB Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology: 2005; 65 12 1863 1872 (Pubitemid 43970103)
88. Bradshaw J. M., Saling M., Anderson V., Hopwood M., Brodtmann A. Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer's type and controls. J Neurol Neurosurg Psychiatry: 2006; 77 10 1129 1135 (Pubitemid 44453246)
89. Mori E., Shimomura T., Fujimori M., et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol: 2000; 57 4 489 493 (Pubitemid 30212121)
90. Jellinger K. A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol: 2008; 116 1 1 16
91. Fujimi K., Sasaki K., Noda K., et al. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama study. Brain Pathol: 2008; 18 3 317 325 (Pubitemid 351782854)
92. Taylor J. P., O'Brien J. Neuroimaging of dementia with Lewy bodies. Neuroimaging Clin N Am: 2012; 22 1 67 81, viii viii.
93. Ballmaier M., O'Brien J. T., Burton E. J., et al. Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neuroimage: 2004; 23 1 325 335 (Pubitemid 39119463)
94. Barber R., Ballard C., McKeith I. G., Gholkar A., O'Brien J. T. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology: 2000; 54 6 1304 1309 (Pubitemid 30174051)
95. Kantarci K., Ferman T. J., Boeve B. F., et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology: 2012; 79 6 553 560
96. Marshall V. L., Patterson J., Hadley D. M., Grosset K. A., Grosset D. G. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun: 2006; 27 12 933 937 (Pubitemid 44706887)
97. McKeith I., O'Brien J., Walker Z., et al. DLB Study Group Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol: 2007; 6 4 305 313 (Pubitemid 46367938)
98. Walker Z., Jaros E., Walker R. W., et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry: 2007; 78 11 1176 1181 (Pubitemid 350057277)
99. O'Brien J. T., McKeith I. G., Walker Z., et al. DLB Study Group Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry: 2009; 194 1 34 39
100. Kantarci K., Lowe V. J., Boeve B. F., et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging: 2011; Oct 20
101. Stamelou M., de Silva R., Arias-Carrión O., et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain: 2010; 133 Pt 6 1578 1590
102. Mackenzie I. R., Munoz D. G., Kusaka H., et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol: 2011; 121 2 207 218
103. Rabinovici G. D., Miller B. L. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs: 2010; 24 5 375 398
104. Rohrer J. D., Guerreiro R., Vandrovcova J., et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology: 2009; 73 18 1451 1456
105. Seelaar H., Kamphorst W., Rosso S. M., et al. Distinct genetic forms of frontotemporal dementia. Neurology: 2008; 71 16 1220 1226
106. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron: 2011; 72 2 245 256
107. Renton A. E., Majounie E., Waite A., et al. ITALSGEN Consortium A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron: 2011; 72 2 257 268
108. Piguet O., Hornberger M., Mioshi E., Hodges J. R. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol: 2011; 10 2 162 172
109. Rascovsky K., Hodges J. R., Knopman D., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: 2011; 134 Pt 9 2456 2477
110. Josephs K. A., Hodges J. R., Snowden J. S., et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol: 2011; 122 2 137 153
111. Kipps C. M., Nestor P. J., Fryer T. D., Hodges J. R. Behavioural variant frontotemporal dementia: not all it seems? Neurocase: 2007; 13 4 237 247 (Pubitemid 350153953)
112. Rosen H. J., Gorno-Tempini M. L., Goldman W. P., et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology: 2002; 58 2 198 208 (Pubitemid 34084208)
113. Kipps C. M., Davies R. R., Mitchell J., Kril J. J., Halliday G. M., Hodges J. R. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord: 2007; 23 5 334 342 (Pubitemid 46631941)
114. Seeley W. W., Crawford R., Rascovsky K., et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol: 2008; 65 2 249 255 (Pubitemid 351240789)
115. Whitwell J. L., Przybelski S. A., Weigand S. D., et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain: 2009; 132 Pt 11 2932 2946
116. Davatzikos C., Resnick S. M., Wu X., Parmpi P., Clark C. M. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage: 2008; 41 4 1220 1227
117. Foster N. L., Heidebrink J. L., Clark C. M., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain: 2007; 130 Pt 10 2616 2635 (Pubitemid 47511706)
118. McNeill R., Sare G. M., Manoharan M., et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. J Neurol Neurosurg Psychiatry: 2007; 78 4 350 355 (Pubitemid 46580539)
119. Tartaglia M. C. Frontotemporal lobar degeneration: new understanding brings new approaches. Neuroimaging Clin N Am: 2012; 22 1 83 97, viii viii
120. Zhang Y., Schuff N., Du A. T., et al. White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain: 2009; 132 Pt 9 2579 2592
121. Tartaglia M. C., Zhang Y., Racine C., et al. Executive dysfunction in frontotemporal dementia is related to abnormalities in frontal white matter tracts. J Neurol: 2012; 259 6 1071 1080
122. Zhou J., Greicius M. D., Gennatas E. D., et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain: 2010; 133 Pt 5 1352 1367
123. Hodges J. R., Patterson K., Oxbury S., Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain: 1992; 115 Pt 6 1783 1806 (Pubitemid 23054865)
124. Hodges J. R., Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol: 2007; 6 11 1004 1014 (Pubitemid 47562322)
125. Seeley W. W., Bauer A. M., Miller B. L., et al. The natural history of temporal variant frontotemporal dementia. Neurology: 2005; 64 8 1384 1390 (Pubitemid 40570506)
126. Chan D., Anderson V., Pijnenburg Y., et al. The clinical profile of right temporal lobe atrophy. Brain: 2009; 132 Pt 5 1287 1298
127. Gorno-Tempini M. L., Murray R. C., Rankin K. P., Weiner M. W., Miller B. L. Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase: 2004; 10 6 426 436
128. Gorno-Tempini M. L., Rankin K. P., Woolley J. D., Rosen H. J., Phengrasamy L., Miller B. L. Cognitive and behavioral profile in a case of right anterior temporal lobe neurodegeneration. Cortex: 2004; 40 4-5 631 644 (Pubitemid 39303093)
129. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol: 2010; 6 2 88 97
130. Mummery C. J., Patterson K., Price C. J., Ashburner J., Frackowiak R. S., Hodges J. R. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol: 2000; 47 1 36 45 (Pubitemid 30033648)
131. Rosen H. J., Kramer J. H., Gorno-Tempini M. L., Schuff N., Weiner M., Miller B. L. Patterns of cerebral atrophy in primary progressive aphasia. Am J Geriatr Psychiatry: 2002; 10 1 89 97 (Pubitemid 34052907)
132. Rohrer J. D., Warren J. D., Modat M., et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology: 2009; 72 18 1562 1569
133. Sapolsky D., Bakkour A., Negreira A., et al. Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia. Neurology: 2010; 75 4 358 366
134. Josephs K. A., Duffy J. R., Strand E. A., et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain: 2006; 129 Pt 6 1385 1398 (Pubitemid 43999372)
135. Ogar J., Slama H., Dronkers N., Amici S., Gorno-Tempini M. L. Apraxia of speech: an overview. Neurocase: 2005; 11 6 427 432 (Pubitemid 43101850)
136. Nestor P. J., Graham N. L., Fryer T. D., Williams G. B., Patterson K., Hodges J. R. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain: 2003; 126 Pt 11 2406 2418 (Pubitemid 37314431)
137. Rebeiz J. J., Kolodny E. H., Richardson E. P. Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol: 1968; 18 1 20 33
138. Steele J. C., Richardson J. C., Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol: 1964; 10 333 359
139. Boeve B. F., Lang A. E., Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol: 2003; 54 05 S15 S19 (Pubitemid 36760148)
140. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology: 1996; 47 1 1 9 (Pubitemid 26243849)
141. Mathew R., Bak T. H., Hodges J. R. Diagnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry: 2012; 83 4 405 410
142. Litvan I., Agid Y., Jankovic J., et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology: 1996; 46 4 922 930 (Pubitemid 26134627)
143. Boeve B. F. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci: 2011; 45 3 350 353
144. Kertesz A., McMonagle P., Blair M., Davidson W., Munoz D. G. The evolution and pathology of frontotemporal dementia. Brain: 2005; 128 Pt 9 1996 2005 (Pubitemid 41253267)
145. Kouri N., Whitwell J. L., Josephs K. A., Rademakers R., Dickson D. W. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol: 2011; 7 5 263 272
146. Williams D. R., Lees A. J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol: 2009; 8 3 270 279
147. Boxer A. L., Geschwind M. D., Belfor N., et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol: 2006; 63 1 81 86 (Pubitemid 43063865)
148. Josephs K. A., Whitwell J. L., Dickson D. W., et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging: 2008; 29 2 280 289
149. Oba H., Yagishita A., Terada H., et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology: 2005; 64 12 2050 2055 (Pubitemid 40880991)
150. Hussl A., Mahlknecht P., Scherfler C., et al. Diagnostic accuracy of the magnetic resonance parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord: 2010; 25 14 2444 2449
151. Whitwell J. L., Jack C. R. Jr, Boeve B. F., et al. Imaging correlates of pathology in corticobasal syndrome. Neurology: 2010; 75 21 1879 1887
152. Borroni B., Premi E., Agosti C., et al. CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder. J Neurol Neurosurg Psychiatry: 2011; 82 8 834 838
153. Hu W. T., Rippon G. W., Boeve B. F., et al. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord: 2009; 24 9 1375 1379
154. Whitwell J. L., Josephs K. A. Neuroimaging in frontotemporal lobar degeneration-predicting molecular pathology. Nat Rev Neurol: 2011; 8 3 131 142
155. Rohrer J. D., Lashley T., Schott J. M., et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain: 2011; 134 Pt 9 2565 2581
156. Whitwell J. L., Jack C. R. Jr, Parisi J. E., et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci: 2011; 45 3 372 378
157. Whitwell J. L., Jack C. R. Jr, Parisi J. E., et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology: 2010; 75 24 2212 2220
158. Urwin H., Josephs K. A., Rohrer J. D., et al. FReJA Consortium FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol: 2010; 120 1 33 41
159. McMillan C. T., Brun C., Siddiqui S., et al. White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration. Neurology: 2012; 78 22 1761 1768
160. McMillan C., Irwin D., Powers J., et al. White matter helps in vivo dissociation between tau from TDP-43 in frontotemporal degeneration. Paper presented at: The 8th International Conference on Frontotemporal Dementias; September 5-7, 2012; Manchester, England
161. Borroni B., Alberici A., Premi E., et al. Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation
162. Borroni B., Alberici A., Cercignani M., et al. Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. Neurobiol Aging: 2012; 33 10 2506 2520
163. Whitwell J. L., Josephs K. A., Avula R., et al. Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology: 2011; 77 9 866 874
164. Mueller S. G., Weiner M. W., Thal L. J., et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement: 2005; 1 1 55 66 (Pubitemid 43348857)
165. Bateman R. J., Aisen P. S., De Strooper B., et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther: 2011; 3 1 1